Ryuichi Onose

Ryuichi Onose is building around an accessible specimen that conventional cancer screening often overlooks: urine. The platform analyses microRNA patterns to assess risk across several cancers, aiming to make an initial check easier to obtain than imaging or invasive sampling. By 2025, the company reported a clinical-sample base exceeding 30,000 and published ongoing research across detection and biological modeling. A US$22 million financing round supported expansion and evidence generation.

Onose's contribution is the integration of biomarker discovery, consumer access, laboratory operations and longitudinal data. In Japan, where participation and capacity can constrain screening programmes, a mailed or clinic-collected urine sample offers a plausible low-friction entry point. The company's BioAI work also uses the accumulating molecular dataset to investigate disease signals beyond a single classifier.

The evidence requires careful separation. Service volume and case stories are company-reported, and a positive risk assessment is not a cancer diagnosis. The platform's expansion does not replace pivotal prospective trials, jurisdiction-specific authorization or evidence that its use reduces late diagnosis or mortality. Onose is ranked for building a serious molecular-diagnostics programme at scale, not for outcomes that the public record has not yet established.